KR102775325B1 - Composition for the prevention, improvement or treatment of inflammation or atopy, comprising Mentha arvensis essential oil as an active ingredient - Google Patents

Abstract

The composition containing peppermint ( Mentha arvensis ) essential oil of the present invention as an active ingredient is non-toxic, effectively inhibits the production of inflammatory substances through regulation of the ERK/NF-κB pathway, and significantly reduces the infiltration of mast cells caused by atopy in an atopic animal model, and thus has excellent efficacy in preventing, improving, or treating atopy, and thus can be usefully utilized in the manufacture of competitive cosmetics, foods, and pharmaceuticals.

Description

Composition for the prevention, improvement or treatment of inflammation or atopy, comprising Mentha arvensis essential oil as an active ingredient

The present invention relates to a composition for preventing, improving or treating atopic dermatitis, comprising peppermint ( Mentha arvensis ) essential oil as an effective ingredient.

The skin is the largest organ of the body, protecting against external physical and chemical stimuli, and plays a role in immune function, preventing water loss, and maintaining body temperature. Skin with impaired function due to genetic and environmental factors can cause chronic inflammatory skin diseases such as atopic dermatitis. According to a 2017 survey, 17.2% of children under 10 years old, 14.6% of adolescents, and 5.5% of adults in Korea suffer from atopic dermatitis. Recently, the prevalence of atopic dermatitis has been increasing not only in Korea but also worldwide due to exposure to polluted environments. Atopic dermatitis is accompanied by symptoms such as dryness, lichen, and erythema, and is accompanied by severe itching, so most patients do not easily improve the affected area. Therefore, there is a need for a treatment that can alleviate and treat atopic dermatitis symptoms, but treatment is difficult because the exact pathogenesis has not been identified. Currently, moisturizers, antihistamines, and topical steroids are being used to relieve symptoms of atopic dermatitis, but caution is needed when using these drugs as they can cause side effects such as diabetes and high blood pressure.

Atopic dermatitis is an inflammatory response caused by an abnormal immune response due to a decline in the skin barrier function, and Nuclear factor-κB (NF-κB) is known as an important mediator of inflammation and immune response in atopic dermatitis. NF-κB is regulated by mitogen-activated protein kinase (MAPK) to produce inflammatory cytokines and chemokines, thereby inducing inflammation. Overexpression of inflammatory cytokines can further activate the inflammatory response, causing genetic mutations and tissue damage, and overexpression of chemokines can produce inflammatory mediators, causing pain, swelling, fever, etc. Therefore, it is possible to treat various inflammatory diseases by controlling the production of inflammatory cytokines and chemokines through the NF-κB/MAPK pathway.

Among natural products that improve excessive inflammatory responses in the body and exhibit preventive, ameliorating or therapeutic effects on atopic dermatitis while having few side effects, peppermint essential oil was used to effectively suppress the production of inflammatory cytokines and chemokines through the NF-κB/MAPK pathway in mouse macrophages. In addition, it was confirmed that it has an anti-inflammatory effect by suppressing the production of inflammatory substances in human-derived keratinocytes, and this was applied to an atopic dermatitis animal model. Peppermint essential oil was confirmed to have an effect of improving or treating clinical symptoms of atopic dermatitis, such as reducing the thickness of the ears and back and reducing mast cell infiltration in an atopic dermatitis animal model, thereby completing the present invention.

Korean Patent Registration No. 10-2020-0082648

The purpose of the present invention is to provide a health functional food composition, a feed composition, a pharmaceutical composition, and a cosmetic composition for improving inflammation and atopy, which contain a fat-soluble fraction extract of peppermint ( Mentha arvensis ) as an effective ingredient.

To achieve the above purpose, the present invention provides a health functional food composition for preventing or improving inflammation or atopic dermatitis, containing peppermint ( Mentha arvensis ) essential oil as an effective ingredient.

In one embodiment of the present invention, the ‘peppermint’ may include at least one of the leaves, stems, roots, and whole plants of peppermint, but is not limited thereto.

In one embodiment of the present invention, the ‘peppermint essential oil’ may be extracted by any one of a steam distillation extraction method, a supercritical extraction method, a pressing method, a solvent extraction method, a cold steeping method, and a warm steeping method, but is not limited thereto.

In one embodiment of the present invention, the 'composition' may be one that reduces NO production, reduces PGE ₂ production, reduces iNOS expression, reduces COX-2 expression, reduces IL-1β expression, and reduces IL-6 expression, but is not limited thereto.

In one embodiment of the present invention, the ‘composition’ may reduce phosphorylation of ERK, reduce phosphorylation of p65, and reduce the expression level of NLRP3, but is not limited thereto.

In one embodiment of the present invention, the 'composition' may be characterized by, but is not limited to, reducing NO production, reducing PGE ₂ production, and reducing IL-1β expression.

In one embodiment of the present invention, the ‘composition’ may be characterized by improving external symptoms of atopic dermatitis and effectively improving epidermal thickness and mast cell infiltration, but is not limited thereto.

In one embodiment of the present invention, the ‘cosmetic composition’ may be formulated in a formulation selected from among toner, essence, foundation, powder, lip balm, cream, pack, gel, lotion, ointment, patch, mask, and spray, but is not limited thereto.

In addition, to achieve the above purpose, the present invention provides a feed composition for preventing or improving inflammation or atopic dermatitis, which contains peppermint ( Mentha arvensis ) essential oil as an effective ingredient.

In addition, in order to achieve the above purpose, the present invention provides a pharmaceutical composition for preventing or treating inflammation or atopic dermatitis, which contains peppermint ( Mentha arvensis ) essential oil as an effective ingredient.

In one embodiment of the present invention, the ‘pharmaceutical composition’ may be formulated in the form of an oral preparation, an injectable preparation, or an external preparation, but is not limited thereto.

In one embodiment of the present invention, the ‘external agent’ may be selected from, but is not limited to, a cream, a gel, an ointment, an emulsion, a suspension, a spray, and a transdermal delivery patch.

Finally, in order to solve the above-mentioned problem and achieve the above-mentioned purpose, the present invention provides a cosmetic composition for preventing or improving inflammation or atopic dermatitis, which contains peppermint ( Mentha arvensis ) essential oil as an effective ingredient.

The present invention relates to a composition containing peppermint essential oil as an effective ingredient, which has the function of preventing, improving or treating inflammation or atopic dermatitis. More specifically, the composition improves external symptoms of atopic dermatitis and effectively improves epidermal thickness and mast cell infiltration, and thus can be used as a health functional food composition, a feed composition, a pharmaceutical composition or a cosmetic composition.

Figure 1 is a graph showing the survival rate of cells exposed to peppermint essential oil of the present invention (a; mouse macrophages, b; human-derived keratinocytes).
Figure 2 is a graph showing the anti-inflammatory effect of peppermint essential oil in RAW 264.7 cells, which are macrophages (a; NO concentration quantified by NO assay in the cell culture medium, b; _PGE2 concentration quantified by ELISA kit, c; iNOS mRNA expression level measured by RT-qPCR, d; COX-2 mRNA expression level measured by RT-qPCR, e; iNOS protein expression level determined by western blot, f; COX-2 protein expression level determined by western blot, g; IL-6 mRNA expression level measured by RT-qPCR, h; IL-1β mRNA expression level measured by RT-qPCR, i; COX-2 protein expression level quantified by ELISA kit, j; IL-1β protein expression level quantified by ELISA kit).
Figure 3 is a graph showing the changes in the inflammatory mechanism in mouse macrophages induced by LPS of peppermint essential oil (a; the degree of phosphorylation of ERK, one of MAPKs; b; the degree of phosphorylation of p65, one of NF-κB; c; the decrease in NLRP3 protein, the most important factor of the inflammasome regulatory complex).
Figure 4 is a graph showing the anti-inflammatory effect of peppermint essential oil in cells induced by HaCaT cells, which are human keratinocyte cells (a; NO concentration quantified by NO assay, b; PGE ₂ concentration quantified by ELISA kit, c; iNOS mRNA expression level measured by RT-qPCR, d; COX-2 mRNA expression level measured by RT-qPCR, e; iNOS protein expression level confirmed by western blot, f; COX-2 protein expression level measured by RT-qPCR, g; IL-6 mRNA expression level measured by RT-qPCR, h; IL-1β mRNA expression level measured by RT-qPCR, i; IL-6 protein expression level quantified by ELISA kit, j; IL-1β protein expression level quantified by ELISA kit).
Figure 5 is a graph showing the atopic dermatitis-improving effect of peppermint essential oil in DNCB-induced cells (a; experimental schedule, b; change in body weight during the experimental period, c; ear thickness on the 21st day of the experiment, d; dermatitis score values of the back at 7-day intervals, e; clinical symptoms and H&E staining and toluidine blue images of the back of each group on the 1st day of the experiment, f; epidermal thickness confirmed by H&E staining, g; degree of mast cell infiltration through toluidine blue staining).

The present invention provides a health functional food composition for preventing or improving inflammation or atopic dermatitis, containing peppermint ( Mentha arvensis ) essential oil as an effective ingredient.

In addition, the present invention provides a feed composition for preventing or improving inflammation or atopic dermatitis, which contains peppermint ( Mentha arvensis ) essential oil as an effective ingredient.

In addition, a pharmaceutical composition for preventing or treating inflammation or atopic dermatitis containing peppermint ( Mentha arvensis ) essential oil as an active ingredient is provided.

In addition, the present invention provides a cosmetic composition for preventing or improving inflammation or atopic dermatitis, which contains peppermint ( Mentha arvensis ) essential oil as an effective ingredient.

In one aspect, the present invention relates to a health functional food composition for preventing or improving inflammation or atopic dermatitis, comprising peppermint ( Mentha arvensis ) essential oil as an effective ingredient.

Throughout this specification, the peppermint includes at least one of the leaves, stems, roots and whole plants of peppermint.

Throughout this specification, the peppermint essential oil is a fat-soluble fraction extract extracted by one or more of steam distillation extraction, supercritical extraction, pressing, solvent extraction, cold steeping, and hot steeping methods.

Throughout this specification, the inflammation is attributed to gram-negative bacteria present in an outer membrane induced by lipopolysaccharide.

In addition, the composition is characterized by, but is not limited to, reducing NO production, reducing PGE ₂ production, reducing iNOS expression, reducing COX-2 expression, reducing IL-1βd expression, and reducing IL-6 expression.

In addition, the composition is characterized by, but is not limited to, reducing phosphorylation of ERK, reducing phosphorylation of p65, and reducing the expression level of NLRP3.

In addition, the composition is characterized by, but is not limited to, reducing NO production, reducing the production of PGE ₂ , and reducing the expression of IL-1β.

In addition, the composition is characterized by improving external symptoms of atopic dermatitis and effectively improving epidermal thickness and mast cell infiltration, but is not limited thereto.

The health functional food composition of the present invention may contain, in addition to containing an extract as an effective ingredient, various flavoring agents or natural carbohydrates as additional ingredients, like a conventional food composition.

Examples of the natural carbohydrates mentioned above are monosaccharides such as glucose, fructose, etc.; disaccharides such as maltose, sucrose, etc.; and common sugars such as polysaccharides such as dextrin, cyclodextrin, etc., and sugar alcohols such as xylitol, sorbitol, erythritol, etc. As the flavoring agent mentioned above, natural flavoring agent (thaumatin), stevia extract (e.g. rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agent (saccharin, aspartame, etc.) can be advantageously used. The food composition of the present invention can be formulated in the same manner as the pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gum, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplements.

In addition, the food composition may contain, in addition to the extract as an effective ingredient, various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickeners (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the food composition of the present invention may contain fruit pulp for the production of natural fruit juice and fruit juice drinks and vegetable drinks.

The functional food composition of the present invention can be manufactured and processed in the form of tablets, capsules, powder, granules, liquid, pills, etc. The term "health functional food composition" in the present invention refers to a food manufactured and processed using raw materials or ingredients having functionality useful to the human body according to Act No. 6727 on Health Functional Foods, and means being consumed for the purpose of obtaining useful effects for health purposes such as regulating nutrients for the structure and function of the human body or physiological effects. The health functional food of the present invention may include conventional food additives, and whether it is suitable as a food additive is determined by the specifications and standards for the relevant item according to the general provisions and general test methods of the Food Additives Codex approved by the Ministry of Food and Drug Safety, unless otherwise specified. Items listed in the "Food Additives Codex" include, for example, chemical synthetic substances such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, sulphate pigment, and guar gum; Examples thereof include mixed preparations such as sodium glutamate preparations, noodle-added alkaline agents, preservative preparations, and tar color preparations. For example, a health functional food in the form of a tablet can be prepared by mixing the effective ingredient of the present invention with excipients, binders, disintegrants, and other additives, granulating a mixture using a conventional method, and then adding a lubricant, etc. to compress and molding, or by directly compressing and molding the mixture. In addition, the health functional food in the form of a tablet can contain a coupling agent, etc., if necessary. Among the health functional foods in the form of a capsule, hard capsules can be prepared by filling a mixture of the effective ingredient of the present invention with additives such as excipients into a conventional hard capsule, and soft capsules can be prepared by filling a mixture of the effective ingredient of the present invention with additives such as excipients into a capsule base such as gelatin. The soft capsules can contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, etc., if necessary. The ring-shaped health functional food can be prepared by molding a mixture of the active ingredient of the present invention with excipients, binders, disintegrants, etc., using a conventionally known method, and, if necessary, can be coated with white sugar or other coating agents, or the surface can be coated with a substance such as starch or talc. The granular health functional food can be manufactured into a granular form by mixing a mixture of the active ingredient of the present invention with excipients, binders, disintegrants, etc., using a conventionally known method, and can contain a flavoring agent, a flavoring agent, etc., if necessary.

In one aspect, the present invention relates to a feed composition for preventing or improving inflammation or atopic dermatitis, comprising peppermint ( Mentha arvensis ) essential oil as an effective ingredient.

The feed composition of the present invention can be expected to have the effect of replacing existing antibiotics and inhibiting the growth of harmful food pathogens, thereby improving the health of animals, improving the weight gain and meat quality of livestock, and increasing milk production and immunity. The feed composition of the present invention can be manufactured in the form of fermented feed, compound feed, pellets, silage, etc. The fermented feed can be manufactured by fermenting organic matter by adding various microbial groups or enzymes other than the peptide of the present invention, and the compound feed can be manufactured by mixing various types of general feed with the peptide of the present invention. The pellet feed can be manufactured by applying heat and pressure to the compound feed, etc. in a pelletizer, and the silage can be manufactured by fermenting green feed with the microorganism according to the present invention. Wet fermented feed can be manufactured by collecting and transporting organic matter such as food waste, mixing it with a sterilizing process and excipients for moisture control at a certain ratio, and fermenting it for 24 hours or more at a temperature suitable for fermentation so that the moisture content is adjusted to about 70%. Fermented dried feed can be manufactured by adding a drying process to wet fermented feed so that the moisture content is adjusted to about 30% to 40%.

The feed composition of the present invention may further include ingredients added to conventional feed. Examples of ingredients added to such feed may include grain powder, meat powder, and legumes. The grain powder may be at least one selected from rice powder, wheat flour, barley powder, and corn powder. The meat powder may be a powdered meat powder obtained by pulverizing at least one selected from chicken, beef, pork, and ostrich meat. The legumes may be at least one selected from soybeans, kidney beans, peas, and black beans.

The feed composition of the present invention may, in addition to the ingredients added to the conventional feed, such as grain powder, meat powder, and legumes, mentioned above, add at least one selected from nutrients and minerals to increase the nutritional value of the feed, and may include at least one selected from antifungal agents, antioxidants, anticoagulants, emulsifiers, and binders to prevent deterioration of feed quality.

In one aspect, the present invention relates to a pharmaceutical composition for preventing or treating inflammation or atopic dermatitis, comprising peppermint ( Mentha arvensis ) essential oil as an active ingredient.

The pharmaceutical composition of the present invention may additionally include an adjuvant in addition to the active ingredient. Any adjuvant known in the art may be used without limitation, but, for example, Freund's complete adjuvant or incomplete adjuvant may be further included to increase the immunogenicity.

The pharmaceutical composition according to the present invention can be prepared in a form in which the active ingredient is mixed with a pharmaceutically acceptable carrier. Here, the pharmaceutically acceptable carrier includes carriers, excipients, and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers that can be used in the pharmaceutical composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.

The pharmaceutical composition of the present invention can be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, or sterile injectable solutions, respectively, according to conventional methods.

When formulated, it can be prepared using diluents or excipients such as fillers, bulking agents, binders, wetting agents, disintegrating agents, and surfactants that are commonly used. Solid preparations for oral administration include tablets, pills, powders, granules, and capsules, and such solid preparations can be prepared by mixing the active ingredient with at least one excipient, such as starch, calcium carbonate, sucrose, lactose, and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc can also be used. Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups, and in addition to commonly used diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives can be included. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases may include witepsol, Tween 61, cocoa butter, laurin butter, and glycerogelatin.

The pharmaceutical composition according to the present invention can be administered to a subject by various routes. All modes of administration are contemplated, for example, oral, intravenous, intramuscular, subcutaneous, and intraperitoneal injection.

The above pharmaceutical composition can be formulated into various oral or parenteral dosage forms.

Oral dosage forms include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsions, syrups, granules, etc., and these dosage forms may further contain, in addition to the active ingredient, a diluent (for example, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and/or glycine), a lubricant (for example, silica, talc, stearic acid and its magnesium or calcium salts, and/or polyethylene glycol). In addition, the tablets may contain a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidine, and, if desired, a disintegrating agent or an effervescent mixture such as starch, agar, alginic acid or its sodium salt, and/or an absorbent, a coloring agent, a flavoring agent, and a sweetening agent. The above formulation can be prepared by conventional mixing, granulating or coating methods.

In addition, a representative example of a formulation for parenteral administration is an injectable preparation, and water, Ringer's solution, isotonic saline solution, or suspension can be used as a solvent for the injectable preparation. The sterile fixed oil of the injectable preparation can be used as a solvent or suspending medium, and any non-irritating fixed oil, including mono- and di-glycerides, can be used for this purpose.

Additionally, the above injectable preparation may use a fatty acid such as oleic acid.

In one aspect, the present invention relates to a cosmetic composition for preventing or improving inflammation or atopic dermatitis, comprising peppermint ( Mentha arvensis ) essential oil as an active ingredient.

The “cosmetic composition” of the present invention can be manufactured by including a cosmetically effective amount of an extract extracted from the essential oil of peppermint ( Mentha arvensis ) of the present invention described above and a cosmetically acceptable carrier.

The term “cosmetically effective amount” as used herein means an amount of the composition of the present invention sufficient to prevent and improve epidermal inflammation or sepsis.

The external form of the cosmetic composition contains a cosmetically or dermatologically acceptable medium or base. It may be provided in any formulation suitable for topical application, for example in the form of a solution, a gel, a solid, a pasty anhydrous product, an emulsion obtained by dispersing an oil phase in an aqueous phase, a suspension, a microemulsion, a microcapsule, a microgranule or a vesicular dispersion of ionic (liposomes) and nonionic types, or in the form of a cream, a skin, a lotion, a powder, an ointment, a spray or a concealer stick. These compositions can be prepared according to methods conventional in the art. The composition according to the invention can also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.

The cosmetic composition according to one embodiment of the present invention is not particularly limited in its formulation, and may be formulated as cosmetics such as, for example, a softening toner, an astringent toner, a nourishing toner, a nourishing cream, a massage cream, an essence, an eye cream, an eye essence, a cleansing cream, a cleansing foam, a cleansing water, a pack, a powder, a body lotion, a body cream, a body oil, and a body essence.

When the cosmetic composition of the present invention is in the form of a paste, cream or gel, animal fiber, plant fiber, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component.

When the cosmetic composition of the present invention is in the form of a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and particularly in the case of a spray, a propellant such as chlorofluorohydrocarbon, propane/butane or dimethyl ether may be additionally included.

When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, a solvating agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.

When the formulation of the cosmetic composition of the present invention is a suspension, liquid diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth, etc. can be used as carrier components.

When the formulation of the cosmetic composition of the present invention is a surfactant-containing cleansing, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkyl amidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolenic derivative, or ethoxylated glycerol fatty acid ester may be used as a carrier component.

The cosmetic composition of the present invention can be applied to cosmetics such as skin, lotion, cream, essence, pack, foundation, color cosmetics, sunscreen, two-way cake, face powder, compact, makeup base, skin cover, eye shadow, lipstick, lip gloss, lip fix, eyebrow pencil, toner, and cleansing agents such as shampoo and soap.

A cosmetic composition according to one embodiment of the present invention may further include, in addition to the extract extracted from the essential oil of Mentha arvensis, a functional additive and an ingredient included in a general cosmetic composition. The functional additive may include an ingredient selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular peptides, high molecular polysaccharides, sphingolipids, and seaweed extracts.

In addition to the functional additives, the cosmetic composition of the present invention may also contain ingredients included in general cosmetic compositions, if necessary. In addition, examples of the contained ingredients include fat components, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, fragrances, blood circulation promoters, cooling agents, antiperspirants, purified water, and the like.

Hereinafter, the present invention will be described in more detail through examples. However, the above examples and experimental examples are presented as examples of the present invention, and if it is judged that a detailed description of a technology or configuration well known to those skilled in the art may unnecessarily obscure the gist of the present invention, the detailed description may be omitted, and the present invention is not limited thereby. The present invention can be variously modified and applied within the scope of the following claims and equivalents interpreted therefrom.

In addition, the terms used in this specification are terms used to appropriately express preferred embodiments of the present invention, and may vary depending on the intention of the user or operator, or the customs of the field to which the present invention belongs. Therefore, the definitions of these terms should be made based on the contents throughout this specification. Throughout the specification, when a part is said to ‘include’ a certain component, this does not mean that other components are excluded, but rather that other components can be further included, unless specifically stated otherwise.

<Preparation Example 1> Extraction of peppermint essential oil (steam distillation method)

The peppermint essential oil used in the present invention was obtained by extracting the whole peppermint plant by steam distillation using a steam distillation apparatus (Hanil Labtech, Korea), and was in the form of a transparent liquid with a spicy aroma. 5 L of distilled water was placed in the steam generation area, 1 kg of dried peppermint plant was placed in the sample loading area, and then 4℃ cooling water was continuously allowed to flow through the cooling tube. The temperature of the steam generation area was maintained at 100℃ for 90 minutes, and the generated steam passed through the dried peppermint plant to extract the essential oil. The extracted essential oil was condensed in the cooling tube and then collected in an essential oil collector, and after passing it through a triangular funnel containing anhydrous sodium sulfate to remove moisture, the essential oil content was measured to obtain the recovery rate. The yield of the peppermint essential oil obtained by repeating the process three times was 1.0580±0.1106% (v/w). The extracted peppermint essential oil was stored in a refrigerator at 4℃ and used for analysis of fragrance chemical components.

<Preparation Example 2> Component Analysis of Peppermint Essential Oil (Steam Distillation Method)

In order to confirm the composition of peppermint essential oil extracted by the steam distillation method used in the present invention, GC-MS analysis was performed under the following conditions using a Varian CP 3800 device (Table 1).

device Varian CP 3800 (Varian, CA, USA) Detector Varian 1200L (Varian, CA, USA) column VF-5ms (30 × 0.25mm x 0.25μm) Injection amount 10μL Oven temperature 50℃(5 minutes) → 250℃(1 minute)
heat rate: 5 ℃/min carrier gas Helium Flow rate 1 mL/min

As a result of GC-MS analysis, it was confirmed that it consists of a total of 49 chemicals. Among them, the main components of peppermint essential oil are menthol (36.27%), menthone (25.71%), and piperitone (9.29%) (Table 2).

No. Compound name Retention time Area (%) 1 Menthol 16.873 36.27 2 Menthone 16.091 25.71 3 Piperitone 19.009 9.29 4 Menthly acetate racemic 19.917 8.30 5 3,5,5-trimethlybicyclo[4.1.0]heptan-2-one 24.068 3.78 6 Limonene 11.748 3.06 7 Menthol 16.422 2.4 8 p-menthane-1,2,3-triol 23.064 1.94 9 β-pinene 9.903 1.07 10 Caryophyllene 23.350 0.88 11 β-cubebene 24.902 0.84 12 1-acetoxy-p-menth-3-one 23.601 0.45 13 Piperitone oxide 18.827 0.44 14 α-pinene 8.287 0.43 15 Menthol 19.356 0.38 16 3-octanol 10.666 0.33 17 β-ocimene 11.985 0.32 18 Bicyclosesquiphellandrene 24.420 0.31 19 Isopulegone 16.580 0.29 20 β-phellandrene 9.733 0.28 21 Linalool 14.162 0.26 22 α-pinene 12.336 0.23 23 Hexen-3-yl valerate 18.292 0.21 24 Pulegone 18.452 0.21 25 2,3-dimethyl-2-cyclopenten-1-one 18.189 0.12 26 D-verbenone 21.258 0.12 27 p-menthane-1,2,3-triol 23.516 0.12 28 α-caryophyllene 24.261 0.12 29 β-bourbonene 22.398 0.15 30 Cubenol 28.110 0.11 31 Diosphenol 20.141 0.10 32 Calamenene 25.854 0.09 33 Butylated hydroxytoluene(BHT) 25.379 0.08 34 α-Cadinol 29.025 0.08 35 β-cadinene 25.779 0.07 36 1,7-dimethyl-4-propan-2-ylcyclodeca-2,7-dien-1-ol 27.204 0.07 37 Eucalyptol (Cineole) 11.846 0.06 38 β-elemente 22.529 0.05 39 Elixene 25.258 0.05 40 γ-cadinene 25.675 0.05 41 α-murolene 26.236 0.05 42 Toluene 3.285 0.04 43 Linalool oxide 13.163 0.04 44 Terpinolene 13.634 0.04 45 Jasmone 22.670 0.04 46 Benzeneacetic acid 28.436 0.04 47 Phytone 32.856 0.04 48 Rose butanoate 24.990 0.03 49 Caryophyllene oxide 27.355 0.03 Total 99.47

<Comparative Example 1> Component Analysis of Peppermint Essential Oil (Supercritical Extraction Method)

The same dried peppermint whole plant was supercritical _CO2 extracted using ISA-SCCO-S-050-500 apparatus. In order to optimize the extraction conditions of peppermint essential oil, the extraction was performed at different pressures (200, 300, 400 bar) and temperatures (40, 50, 60, 70℃). The flow rate of _CO2 (99.5%, w/w pure) was maintained at 30 mL/min, and the essential oil was collected by reducing the pressure after 1 hour of extraction. The amount of extracted essential oil was sampled and measured by weight, and the maximum recovery of peppermint essential oil was 2.38% at 70℃ and 200 bar. The components of the obtained peppermint essential oil were analyzed by GC-MS under the same conditions as in Supplementary Material 2. The analysis results showed that the main components of the supercritical extracted peppermint essential oil were Linolenyl alcohol (50.06%), paeonol (7.50%), and mellein (6.60%) (Table 3).

No. Compound name Retention time Area (%) 1 Linolenyl alcohol 40.237 50.06 2 Paeonol 33.738 7.50 3 Melin 36.940 6.60 4 β-selinene 35.151 5.55 5 (Z)6,(Z)9-Pentadecadien-1-ol 40.106 3.32 6 Caryophyllene oxide 38.008 2.77 7 α-selinene 35.376 2.76 8 Phenylethyl Alcohol 21.667 1.88 9 β-Elemene 31.920 1.59 10 α-Curcumene 34.851 1.58 11 Mercaptoacetic acid 49.784 1.57 12 Nonadecane 38.335 1.41 13 Methyl 7,10,13,16,19-docosapentaenoate 39.561 1.28 14 5,8,11-Heptadecatrien-1-ol 39.951 1.27 15 Propanoic acid 31.367 1.08 16 2,6,10-Trimethyltetradecane 34.907 1.06 17 Copaene 31.450 1.03 18 Caryophyllene 32.929 0.87 19 Propanoic acid 30.539 0.70 20 γ-Nonalactone 31.030 0.70 21 Methyl stearidonate 37.724 0.70 22 Heneicosane 43.814 0.61 23 α-Ionone 33.012 0.56 24 α-Bergamotene 33.310 0.52 25 Pentadecane 32.200 0.51 26 Heptadecane, 2,6,10,15-tetramethyl 36.310 0.46 27 Phenol 39.004 0.40 28 Methyl heptacosanoate 47.009 0.36 29 Ethyl palmitate 48.648 0.36 30 Propanedioic acid 50.907 0.35 31 β-Bisabolen 35.673 0.35 32 Rhodopin 52.453 0.24 Total 100

<Experimental Example 1> Cytotoxicity Evaluation of Peppermint Essential Oil in Mouse Macrophages and Human Keratinocytes

In order to confirm the effect of peppermint essential oil extracted by the steam distillation method used in the present invention on mouse macrophages and human-derived keratinocytes, peppermint essential oil (0, 12.5, 25, 50, and 100 μg/mL) was pretreated. After 24 hours of exposure, the cells were re-cultured in MTT reagent for 4 hours to evaluate the effect of peppermint essential oil. Afterwards, the culture medium was removed, and the stained cells were dissolved in DMSO and isopropanol (1:1) solution, and the absorbance was measured at 540 nm to compare the cell viability.

Figure 1a is a graph showing the survival rate of mouse macrophages exposed to peppermint essential oil.

Figure 1b is a graph showing the survival rate of human-derived keratinocytes exposed to peppermint essential oil. As a result of comparing cell survival rates, it was confirmed that peppermint essential oil had no effect on cells at concentrations below 100 μg/mL. Therefore, it can be seen that the results of the experiments conducted thereafter were also unrelated to cell survival rates.

<Experimental Example 2> Anti-inflammatory effect of peppermint essential oil in mouse macrophages

To confirm the anti-inflammatory effect of peppermint essential oil extracted by the steam distillation method of the present invention, mouse macrophage RAW 264.7 cells were pretreated with peppermint essential oil (12.5, 25, 50, and 100 μg/mL). After 1 hour, 0.1 μg/mL of Lipopolysaccharide (LPS) was treated to induce inflammation. 24 hours after LPS treatment, the cell culture medium was harvested, and the concentrations of NO, PGE ₂ , IL-6, and IL-1β were quantified. In addition, cells were harvested, and changes in mRNA levels of iNOS and COX-2, IL-6, and IL-1β were confirmed using RT-qPCR, and changes in protein levels of iNOS and COX-2 were confirmed using western blot.

Figure 2a is a graph showing the quantitative analysis of the concentration of NO through an NO assay in a cell culture medium. It was confirmed that the concentration of NO increased with LPS and that when the peppermint essential oil of the present invention was pretreated, the amount of NO production decreased in a concentration-dependent manner.

Figure 2b is a graph showing the concentration of PGE ₂ in the culture solution quantified using an ELISA kit. It was confirmed that the concentration of PGE ₂ increased with LPS, and that when the peppermint essential oil of the present invention was pretreated, the production of PGE ₂ decreased in a concentration-dependent manner.

Figure 2c is a graph showing the mRNA expression level of iNOS, an enzyme that produces NO, confirmed by RT-qPCR. It was confirmed that the mRNA expression level of iNOS significantly increased with LPS and significantly decreased with pretreatment with peppermint essential oil of the present invention.

Figure 2d is a graph showing the mRNA expression level of COX-2, an enzyme that produces PGE ₂ , confirmed by RT-qPCR. The mRNA expression level of COX-2 significantly increased with LPS, and was confirmed to significantly decrease when pretreated with 100 μg/mL of peppermint essential oil of the present invention.

Figure 2e is a graph showing the quantitative results of confirming the protein expression level of iNOS. It was confirmed that the protein expression level of iNOS significantly increased with LPS and significantly decreased with pretreatment with peppermint essential oil of the present invention.

Figure 2f is a graph showing the protein expression level of COX-2, an enzyme that produces PGE ₂ , confirmed by western blot. It was confirmed that the protein expression level of COX-2 significantly increased with LPS, and significantly decreased when pretreated with peppermint essential oil of the present invention.

Figure 2g is a graph showing the mRNA expression level of IL-6, an inflammatory cytokine, confirmed by RT-qPCR. It was confirmed that the peppermint essential oil of the present invention suppresses the mRNA expression of IL-6, an inflammatory cytokine induced by LPS, in a concentration-dependent manner.

Figure 2h is a graph showing the mRNA expression level of IL-1β, an inflammatory cytokine, confirmed by RT-qPCR. It was confirmed that the peppermint essential oil of the present invention suppressed the mRNA expression of IL-1β, an inflammatory cytokine induced by LPS, in a concentration-dependent manner.

Figure 2i is a graph showing the protein expression level of IL-6 in a cell culture medium quantified using an ELISA kit. IL-6 induced by LPS was decreased in a concentration-dependent manner by the peppermint essential oil of the present invention.

Figure 2j is a graph showing the protein expression level of IL-1β in a cell culture medium quantified using an ELISA kit. IL-1β induced by LPS was decreased in a concentration-dependent manner by the peppermint essential oil of the present invention.

<Experimental Example 3> Anti-inflammatory mechanism of peppermint essential oil in mouse macrophages

In order to confirm the anti-inflammatory mechanism of peppermint essential oil extracted by the steam distillation method of the present invention, the following experiment was conducted. It is known that Nuclear factor-κB (NF-κB) is regulated by N mitogen-activated protein kinase (MAPK), which is known as a mediator of inflammation and immune response, to produce inflammatory cytokines and chemokines, thereby inducing inflammation. Therefore, to confirm whether the decrease in cytokines and chemokines induced by LPS in Experimental Example 1 by pretreatment with peppermint essential oil was related to the decrease in the expression levels of NF-κB and MAPK, mouse macrophage RAW 264.7 cells were pretreated with peppermint essential oil (12.5, 25, 50, and 100 μg/mL). One hour later, 0.1 μg/mL of Lipopolysaccharide (LPS) was treated to induce inflammation, and 1 hour after LPS treatment, cells were harvested and analyzed by Western blot.

Figure 3a confirmed that phosphorylation of ERK, one of the MAPKs, increased by LPS and decreased in a concentration-dependent manner by pretreatment with peppermint essential oil of the present invention.

Figure 3b confirmed that phosphorylation of p65, one of NF-κB, was increased by LPS and decreased in a concentration-dependent manner by pretreatment with peppermint essential oil of the present invention.

Therefore, peppermint essential oil can be known to suppress inflammation through the ERK/NF-κB pathway. If excessive inflammation persists, the inflammasome is formed, which in turn produces inflammatory cytokines and causes various autoimmune diseases.

Figure 3c shows that NLRP3, the most important factor of the inflammation regulatory complex, was increased by LPS, and that pretreatment with peppermint essential oil of the present invention decreased the protein expression of NLRP3 in a concentration-dependent manner.

<Experimental Example 4> Anti-inflammatory effect of peppermint essential oil on human-derived keratinocytes

Extracted by the steam distillation method of the present invention To confirm the anti-inflammatory effect of peppermint essential oil, human keratinocyte cell line HaCaT cells were pretreated with peppermint essential oil (12.5, 25, 50, and 100 μg/mL). After 1 hour, 0.1 μg/mL of lipopolysaccharide (LPS) was treated to induce inflammation. 24 hours after LPS treatment, the cell culture medium was harvested, and the concentrations of NO, PGE ₂ , IL-6, and IL-1β were quantified. In addition, cells were harvested, and changes in mRNA levels of iNOS and COX-2, IL-6, and IL-1β were confirmed using RT-qPCR, and changes in protein levels of iNOS and COX-2 were confirmed by western blot.

Figure 4a is a graph showing the quantitative analysis of the concentration of NO through an NO assay in a cell culture medium. It was confirmed that the concentration of NO increased with LPS, and that when the peppermint essential oil of the present invention was pretreated, the amount of NO production decreased in a concentration-dependent manner.

Figure 4b is a graph showing the concentration of PGE ₂ in the culture solution quantified using an ELISA kit. It was confirmed that the concentration of PGE ₂ increased with LPS, and that when the peppermint essential oil of the present invention was pretreated, the production of PGE ₂ decreased in a concentration-dependent manner.

Figure 4c is a graph showing the mRNA expression level of iNOS, an enzyme that produces NO, confirmed by RT-qPCR. The mRNA expression level of iNOS significantly increased with LPS, and no significant difference was found with pretreatment with peppermint essential oil of the present invention.

Figure 4d is a graph showing the mRNA expression level of COX-2, an enzyme that produces PGE ₂ , confirmed by RT-qPCR. The mRNA expression level of COX-2 significantly increased with LPS, and it was confirmed that it decreased in a concentration-dependent manner when pretreated with peppermint essential oil of the present invention.

Figure 4e is a graph showing the quantitative results of confirming the protein expression level of iNOS. It was confirmed that the protein expression level of iNOS significantly increased with LPS and significantly decreased with pretreatment with peppermint essential oil of the present invention.

Figure 4f is a graph showing the protein expression level of COX-2, an enzyme that produces PGE ₂ , confirmed by western blot. It was confirmed that the protein expression level of COX-2 significantly increased with LPS, and significantly decreased when pretreated with peppermint essential oil of the present invention.

Figure 4g is a graph showing the mRNA expression level of IL-6, an inflammatory cytokine, confirmed by RT-qPCR. It was confirmed that the peppermint essential oil of the present invention does not inhibit the mRNA expression of IL-6, an inflammatory cytokine induced by LPS.

Figure 4h is a graph showing the mRNA expression level of IL-1β, an inflammatory cytokine, confirmed by RT-qPCR. It was confirmed that the peppermint essential oil of the present invention dose-dependently inhibits the mRNA expression of IL-1β, an inflammatory cytokine induced by LPS.

Figure 4i is a graph showing the protein expression level of IL-6 in a cell culture medium quantified using an ELISA kit. IL-6 induced by LPS was decreased in a concentration-dependent manner by the peppermint essential oil of the present invention.

Figure 4j is a graph showing the protein expression level of IL-1β in a cell culture medium quantified using an ELISA kit. IL-1β induced by LPS was inhibited by the peppermint essential oil of the present invention.

<Experimental Example 5> Effect of peppermint essential oil on atopic improvement in DNCB-induced atopic model

In order to confirm the atopic improvement effect using the peppermint essential oil extracted by the steam distillation method of the present invention, the peppermint essential oil of the present invention was applied to 6-week-old female BALB/c mice. The backs of the BALB/c mice were shaved, and 1% DNCB was applied to the back and ears to sensitize them, and re-applied after 4 days to induce atopy. In order to confirm the atopic improvement effect of peppermint essential oil, 1% and 3% peppermint essential oil were applied to the back and ears every day from the 7th day, and 0.4% DNCB was applied once every two days to maintain the atopy. DNCB was applied 30 minutes after the peppermint essential oil was applied, and dexamethasone (1 mg/kg), used as a positive control group of the present invention, was orally administered at the same time as the peppermint essential oil. Body weight was measured once every 4 days for 8 mice per group, and dermatitis score was measured based on clinical symptoms on the back once every 7 days. On the 21st day, the mice were sacrificed and the ear thickness was measured. Tissues from the back were collected and H&E staining was performed to check the thickness of the stratum corneum and toluidine blue staining was performed to check the infiltration of mast cells.

Figure 5a is an experimental schedule for confirming the atopic improvement effect of peppermint essential oil of the present invention.

Figure 5b is a graph measuring the change in body weight during the experimental period. The positive control group can improve the symptoms of atopic dermatitis, but has the characteristic of weight loss as a side effect. It is thought that the model is well formed as the weight of the positive control group decreased after the experimental substance treatment.

Figure 5c is a graph measuring ear thickness on the 21st day. Compared to the normal group, the ear thickness of the control group significantly increased, and it was confirmed that the peppermint essential oil of the present invention significantly decreased it similarly to the positive control group.

Figure 5d shows the results of measuring the dermatitis score of the back area once every 7 days during the experimental period. Compared to the normal group, the dermatitis score of the control group increased, and it was confirmed that the peppermint essential oil of the present invention improved it similarly to the positive control group.

Figure 5e shows the clinical symptoms and H&E staining and toluidine blue images of the back area of each group on the 21st day. Compared to the normal group, it was confirmed that the clinical symptoms of the back area of the control group were worsened, and when the peppermint essential oil of the present invention was applied, it was confirmed that it was effectively improved at 1%.

Figure 5f is a graph measuring the thickness of the epidermis through H&E staining. Compared to the normal group, the thickness of the epidermis of the control group significantly increased, and the thickness of the epidermis of the group to which peppermint essential oil was applied decreased similarly to the positive control group.

Figure 5g is a graph measuring mast cell infiltration using toluidine blue staining. It was confirmed that mast cell infiltration occurred more frequently in the control group compared to the normal group, and it was confirmed that mast cell infiltration was significantly reduced in the group to which 1% peppermint essential oil of the present invention was applied.

Claims (13)

Contains peppermint ( Mentha arvensis ) essential oil extracted by steam distillation as an effective ingredient.
The above mint is characterized as being a precursor of mint,
The peppermint essential oil includes Menthol, Menthone, Piperitone, Menthly acetate racemic, 3,5,5-trimethlybicyclo[4.1.0]heptan-2-one, Limonene, Menthol, p-menthane-1,2,3-triol, β-pinene, Caryophyllene, β-cubebene, 1-acetoxy-p-menth-3-one, Piperitone oxide, α-pinene, Menthol, 3-octanol, β-ocimene, Bicyclosesquiphellandrene, Isopulegone, β-phellandrene, Linalool, α-pinene, Hexen-3-yl valerate, Pulegone, 2,3-dimethyl-2-cyclopenten-1-one, D-verbenone, p-menthane-1,2,3-triol, α-caryophyllene, β-bourbonene, Cubenol, Diosphenol, Calamenene, Butylated hydroxytoluene (BHT), α-Cadinol, β-cadinene, 1,7-dimethyl-4-propan-2-ylcyclodeca-2,7-dien-1-ol, Eucalyptol (Cineole), β-elemene, Elixene, γ-cadinene, α-murolene, Toluene, Linalool oxide, Contains Terpinolene, JasmoneBenzeneacetic acid, Phytone, Rose butanoate, Caryophyllene oxide,
A health functional food composition for preventing or improving inflammation or atopic dermatitis, wherein the peppermint essential oil contains 36.27% menthol, 25.71% menthone, and 9.29% piperitone as main components. delete delete In the first paragraph,
A health functional food composition for preventing or improving inflammation or atopic dermatitis, characterized in that the composition reduces the amount of NO production, reduces the amount of PGE ₂ production, reduces the amount of iNOS expression, reduces the amount of COX-2 expression, reduces the amount of IL-1βd expression, and reduces the amount of IL-6 expression. In the first paragraph,
A health functional food composition for preventing or improving inflammation or atopic dermatitis, characterized in that the composition reduces phosphorylation of ERK, reduces phosphorylation of p65, and reduces the expression level of NLRP3. In the first paragraph,
A health functional food composition for preventing or improving inflammation or atopic dermatitis, characterized in that the composition reduces NO production, reduces the amount of PGE ₂ produced, and reduces the amount of IL-1β expressed.
In the first paragraph,
The composition is a health functional food composition for preventing or improving inflammation or atopic dermatitis, characterized in that it improves external symptoms of atopic dermatitis and effectively improves epidermal thickness and mast cell infiltration. delete Contains peppermint ( Mentha arvensis ) essential oil extracted by steam distillation as an effective ingredient.
The above mint is characterized as being a precursor of mint,
The peppermint essential oil includes Menthol, Menthone, Piperitone, Menthly acetate racemic, 3,5,5-trimethlybicyclo[4.1.0]heptan-2-one, Limonene, Menthol, p-menthane-1,2,3-triol, β-pinene, Caryophyllene, β-cubebene, 1-acetoxy-p-menth-3-one, Piperitone oxide, α-pinene, Menthol, 3-octanol, β-ocimene, Bicyclosesquiphellandrene, Isopulegone, β-phellandrene, Linalool, α-pinene, Hexen-3-yl valerate, Pulegone, 2,3-dimethyl-2-cyclopenten-1-one, D-verbenone, p-menthane-1,2,3-triol, α-caryophyllene, β-bourbonene, Cubenol, Diosphenol, Calamenene, Butylated hydroxytoluene (BHT), α-Cadinol, β-cadinene, 1,7-dimethyl-4-propan-2-ylcyclodeca-2,7-dien-1-ol, Eucalyptol (Cineole), β-elemene, Elixene, γ-cadinene, α-murolene, Toluene, Linalool oxide, Contains Terpinolene, JasmoneBenzeneacetic acid, Phytone, Rose butanoate, Caryophyllene oxide,
A feed composition for preventing or improving inflammation or atopic dermatitis, wherein the peppermint essential oil contains 36.27% menthol, 25.71% menthone, and 9.29% piperitone as main components. Contains peppermint ( Mentha arvensis ) essential oil extracted by steam distillation as an effective ingredient.
The above mint is characterized as being a precursor of mint,
The peppermint essential oil includes Menthol, Menthone, Piperitone, Menthly acetate racemic, 3,5,5-trimethlybicyclo[4.1.0]heptan-2-one, Limonene, Menthol, p-menthane-1,2,3-triol, β-pinene, Caryophyllene, β-cubebene, 1-acetoxy-p-menth-3-one, Piperitone oxide, α-pinene, Menthol, 3-octanol, β-ocimene, Bicyclosesquiphellandrene, Isopulegone, β-phellandrene, Linalool, α-pinene, Hexen-3-yl valerate, Pulegone, 2,3-dimethyl-2-cyclopenten-1-one, D-verbenone, p-menthane-1,2,3-triol, α-caryophyllene, β-bourbonene, Cubenol, Diosphenol, Calamenene, Butylated hydroxytoluene (BHT), α-Cadinol, β-cadinene, 1,7-dimethyl-4-propan-2-ylcyclodeca-2,7-dien-1-ol, Eucalyptol (Cineole), β-elemene, Elixene, γ-cadinene, α-murolene, Toluene, Linalool oxide, Contains Terpinolene, JasmoneBenzeneacetic acid, Phytone, Rose butanoate, Caryophyllene oxide,
A pharmaceutical composition for preventing or treating inflammation or atopic dermatitis, wherein the peppermint essential oil contains 36.27% menthol, 25.71% menthone, and 9.29% piperitone as main components. In Article 10,
The above pharmaceutical composition is a pharmaceutical composition for preventing or treating inflammation or atopic dermatitis, formulated in the form of an oral preparation, an injectable preparation or an external preparation. In Article 11,
A pharmaceutical composition for preventing or treating inflammation or atopic dermatitis, wherein the external agent is selected from a cream, gel, ointment, emulsion, suspension, spray, and transdermal delivery patch. Contains peppermint ( Mentha arvensis ) essential oil extracted by steam distillation as an effective ingredient.
The above mint is characterized as being a precursor of mint,
The peppermint essential oil includes Menthol, Menthone, Piperitone, Menthly acetate racemic, 3,5,5-trimethlybicyclo[4.1.0]heptan-2-one, Limonene, Menthol, p-menthane-1,2,3-triol, β-pinene, Caryophyllene, β-cubebene, 1-acetoxy-p-menth-3-one, Piperitone oxide, α-pinene, Menthol, 3-octanol, β-ocimene, Bicyclosesquiphellandrene, Isopulegone, β-phellandrene, Linalool, α-pinene, Hexen-3-yl valerate, Pulegone, 2,3-dimethyl-2-cyclopenten-1-one, D-verbenone, p-menthane-1,2,3-triol, α-caryophyllene, β-bourbonene, Cubenol, Diosphenol, Calamenene, Butylated hydroxytoluene (BHT), α-Cadinol, β-cadinene, 1,7-dimethyl-4-propan-2-ylcyclodeca-2,7-dien-1-ol, Eucalyptol (Cineole), β-elemene, Elixene, γ-cadinene, α-murolene, Toluene, Linalool oxide, Contains Terpinolene, JasmoneBenzeneacetic acid, Phytone, Rose butanoate, Caryophyllene oxide,
A cosmetic composition for preventing or improving inflammation or atopic dermatitis, wherein the peppermint essential oil contains 36.27% menthol, 25.71% menthone, and 9.29% piperitone as main components.